A5047790697- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Ultrasound and Hyperthermia Applications
- Cancer Mechanisms and Therapy
- Nutrition and Health in Aging
- Hepatitis B Virus Studies
- Diet, Metabolism, and Disease
- Neuroblastoma Research and Treatments
- Hormonal Regulation and Hypertension
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Soft tissue tumor case studies
- Sarcoma Diagnosis and Treatment
- Gastrointestinal Bleeding Diagnosis and Treatment
- Metabolism and Genetic Disorders
- Metastasis and carcinoma case studies
Tokyo Medical University
2020-2025
Musashino Red Cross Hospital
2021-2023
Weatherford College
2021
Suzuki (Japan)
2021
Seoul National University
2021
Despite the diversity of thermal ablations, such as radiofrequency ablation (RFA) and microwave (MWA), non-thermal ablation, irreversible electroporation (IRE) cross-comparisons multiple ablative modalities for hepatocellular carcinoma (HCC) treatment remain scarce. Thus, we investigated therapeutic outcomes different three in early stage HCC.A total 322 consecutive patients with 366 HCCs (mean tumor size ± standard deviation: 1.7 0.9 cm) who underwent RFA (n = 216, 59.0%), MWA 91, 28.3%),...
The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS HCC non-HCC malignancies based on sensitivity, specificity, positive predictive value (PPV), negative (NPV). Patients with chronic liver disease at risk were evaluated retrospectively. Nodules ≥1 cm arterial phase...
Background Nonalcoholic fatty liver disease (NAFLD) is common in the general population but identifying patients with high-risk nonalcoholic steatohepatitis (NASH) who are candidates for pharmacologic therapy remains a challenge. Purpose To develop score to identify NASH, defined as NASH an NAFLD activity (NAS) of 4 or greater and clinically significant fibrosis (stage 2 [F2] higher). Materials Methods This was cross-sectional secondary analysis data prospectively collected between April...
To investigate changes in skeletal muscle mass and fat fraction patients with metabolic dysfunction-associated steatotic liver disease (MASLD) type 2 diabetes mellitus (T2DM) undergoing treatment Semaglutide for 6months. This single-arm pilot study included 21 MASLD who received semaglutide T2DM. Body weight, parameters, enzymes, fibrosis markers, index (cm2/m2), (%) at the L3 level using two-point Dixon method on magnetic resonance imaging (MRI), as well steatosis stiffness assessed...
The aim of this study was to compare the diagnostic performance Contrast-Enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) version 2017, which includes portal- late-phase washout as a major imaging feature, with that modified CEUS LI-RADS, Kupffer-phase findings feature. Participants at risk hepatocellular carcinoma (HCC) treatment-naïve hepatic lesions (≥1 cm) were recruited underwent Sonazoid-enhanced US. Arterial phase hyperenhancement (APHE), time, echogenicity in...
Abstract A 61-year-old female patient with advanced intrahepatic cholangiocarcinoma diagnosed based on imaging and tumor biopsy findings was treated combination therapy comprising gemcitabine, cisplatin, durvalumab. After eight cycles of durvalumab two subsequent maintenance immunotherapy, significant shrinkage enabled conversion surgery R0 resection. The immune microenvironment has a critical role in predicting the efficacy combined immunotherapy some types cancer; however, its remains...
Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements systemic therapy for HCC are expected increase candidates eligible CS because higher response rate. The aim this study was clarify characteristics patients who underwent tyrosine kinase inhibitor (TKI) therapy.
To compare the diagnostic performance based on modified CEUS Liver Imaging Reporting and Data System (LI-RADS), which includes Kupffer-phase findings as a major imaging feature, with that of CT MRI (CT/MRI) LI-RADS for liver nodules in patients at high risk HCC.A total 120 were included this retrospective study. The median size lesions was 20.0 mm (interquartile range, 14.0-30.8 mm). Of these lesions, 90.0% (108 120) confirmed HCCs, 6.7% (8 intrahepatic cholangiocarcinomas, 1.7% (2...
The effect of hepatic fibrosis stage on quantitative ultrasound based the attenuation coefficient (AC) for liver lipid quantification is controversial. objective this study was to determine how degree assessed by magnetic resonance (MR) elastography affects AC ultrasound-guided parameter according grade steatosis, using imaging (MRI)-derived proton density fat fraction (MRIderived PDFF) as reference standard. Between February 2020 and April 2021, 982 patients with chronic disease who...
This review outlines several modified versions of the contrast-enhanced ultrasonography Liver Imaging Reporting and Data System (CEUS LI-RADS) that utilize Sonazoid. Furthermore, it discusses advantages challenges diagnosing hepatocellular carcinoma using these guidelines, as well authors' expectations opinions regarding next CEUS LI-RADS version. It is possible Sonazoid could be incorporated into version LI-RADS.
Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies advanced HCC has been remarkable, role PIVKA-II is unclear. This prospective study aimed to verify Elecsys compared with Lumipulse in cohort undergoing therapy.A total 62 patients who were treated atezolizumab bevacizumab (ATZ+BEV) molecular targeted agents (MTAs) prospectively enrolled at Musashino Red...
Alanine aminotransferase (ALT) is a criterion for the introduction of nucleotide/nucleoside analog (NA), and ALT levels are decreased by NA treatment. However, association between post-treatment hepatocellular carcinoma (HCC) risk remains unclear. To fill this gap, we aimed to establish target value level during treatment.In total, 413 patients with chronic hepatitis B who received entecavir, tenofovir alafenamide, or disoproxil fumarate were enrolled. The subsequent development HCC was...
The anti-programmed death-ligand 1 antibody atezolizumab and vascular endothelial growth factor-neutralizing bevacizumab in combination (Atezo + Bev) have become the first-line therapy advanced hepatocellular carcinoma (HCC). Distinct types of tumor immune microenvironment (TIME) their associations with specific molecular subclasses driver gene mutations been identified HCC; however, these insights are mainly based on surgically resected early-stage tumors. current study aimed to reveal...
Advanced fibrosis detection in the general population is an unmet need. Additionally, screening method for advanced not established. Thus, this study aimed to examine use of shear wave measurement (SWM), which measures liver stiffness by ultrasound elastography as a tool health checkups that represents population.SWM was performed all subjects. Magnetic resonance (MRE) those with SWM velocity (Vs) ≥1.3 m/s determinate fibrosis. The diagnostic accuracy Vs (determined MRE ≥3.62 kPa) examined....
The study aimed to compare the diagnostic performance of washout-parametric imaging (WOPI) with that conventional contrast-enhanced ultrasound (cCEUS) in differentiating focal liver lesions (FLLs). A total 181 FLLs were imaged using Sonazoid, and recordings captured for 10 minutes a prospective setting. WOPI was constructed from three images, depicting arterial phase (peak enhancement), early portal venous (1-minute post-injection), vasculo-Kupffer (5 or post-injection). intensity variations...
This is the case of a 68-year-old male. On 14th day after introduction atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder on 16th day, steroid pulse therapy started possible encephalitis, which immune-related adverse event (irAE) caused by administration continued because patient's improved, no relapse symptoms observed. Listing irAEs as...